PHAT: Phathom Pharmaceuticals, Inc.
Performance
PHAT -59.77%
Watchlist
Select an item
Summary
PHAT at a glance
PHAT returned -59.77% over the past year and -24.86% a year over five years. Its worst drop in that year was -71.90%, smaller than 4% of stocks on Redstone, and its Sharpe ratio of -1.05 beats 4% of stocks on Redstone. It pays no dividends.
Current Drawdown
-70.52%
Rolling Volatility
89.65%
Actions
Metrics
Risk Indicators
Alpha-79.01%
Beta0.80x
Sharpe-1.05
Sortino-1.30
Omega0.83
Calmar-0.83
Martin-1.75
Profile
About PHAT
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $433M
- Listed
- Oct 2019
- Employees
- 371
- Headquarters
- Florham Park, NJ
- Website
- phathompharma.com
Comparisons